The Immune Function Studies Core (Core C) is designed to support the proposed studies of yc Foamy Virus gene therapy for SCID-Xl that will ufilize in vitro testing in cell lines as well as in vivo testing using pre- clinical animal models. The Core will support all three projects (1, 2, and 3) of this Program Project Grant and is focused primarily on evaluation of funcfional immune recovery after gene therapy in this severe immunodeficiency disorder. The Core will perform mulfi-parameter flow cytometry analyses of human, mouse, and canine cells to measure viral marking and immune reconstitution after yc FV gene therapy. In addifion. Core C will evaluate restoration of specific functional deficits (for example restoration of lL-2 signaling) in yc FV treated cells and will work with the SCRl Immunology Diagnosfic Laboratory (IDL) to analyze funcfional immune responses to neoanfigen (bacteriophage OX174) vaccinafion in treated dogs. Flow cytometry and gene sequencing will be performed by the Core to rapidly identify affected SCID-Xl dogs shortly after birth. Core C personnel will direcfiy assist project investigators in the analysis and interpretation of data generated by the Core. Data from these analyses will be used to evaluate which yc FV vector is most efficacious and which conditioning regimen facilitates the most complete immune recovery.

Public Health Relevance

Immune dysfuncfion and susceptibility to severe, life-threatening infections are the hallmarks of the fatal childhood immunodeficiency disorder, SCID-Xl. Evaluafion of immune reconstitufion and recovery of functional immune responses after potenfially curative gene therapy is therefore vital for judging whether a particular treatment is efficacious. Core C will evaluate immune recovery in this trial of Foamy Viral mediated gene therapy for SCID-Xl.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI097100-01
Application #
8278889
Study Section
Special Emphasis Panel (ZAI1-JTS-I (S1))
Project Start
2012-08-07
Project End
2017-07-31
Budget Start
2012-08-07
Budget End
2013-07-31
Support Year
1
Fiscal Year
2012
Total Cost
$191,091
Indirect Cost
$41,091
Name
Seattle Children's Hospital
Department
Type
DUNS #
048682157
City
Seattle
State
WA
Country
United States
Zip Code
98105
Everson, Elizabeth M; Trobridge, Grant D (2016) Retroviral vector interactions with hematopoietic cells. Curr Opin Virol 21:41-46
Bii, Victor M; Trobridge, Grant D (2016) Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors. Cancers (Basel) 8:
Everson, Elizabeth M; Olzsko, Miles E; Leap, David J et al. (2016) A comparison of foamy and lentiviral vector genotoxicity in SCID-repopulating cells shows foamy vectors are less prone to clonal dominance. Mol Ther Methods Clin Dev 3:16048
Hocum, Jonah D; Linde, Ian; Rae, Dustin T et al. (2016) Retargeted Foamy Virus Vectors Integrate Less Frequently Near Proto-oncogenes. Sci Rep 6:36610
Adair, Jennifer E; Waters, Timothy; Haworth, Kevin G et al. (2016) Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. Nat Commun 7:13173
Humbert, Olivier; Gisch, Don W; Wohlfahrt, Martin E et al. (2016) Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells. Mol Ther 24:1237-46
Browning, Diana L; Collins, Casey P; Hocum, Jonah D et al. (2016) Insulated Foamy Viral Vectors. Hum Gene Ther 27:255-66
Rae, Dustin T; Collins, Casey P; Hocum, Jonah D et al. (2015) Modified Genomic Sequencing PCR Using the MiSeq Platform to Identify Retroviral Integration Sites. Hum Gene Ther Methods 26:221-7
Felsburg, Peter J; De Ravin, Suk See; Malech, Harry L et al. (2015) Gene therapy studies in a canine model of X-linked severe combined immunodeficiency. Hum Gene Ther Clin Dev 26:50-6
Gori, Jennifer L; Butler, Jason M; Chan, Yan-Yi et al. (2015) Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells. J Clin Invest 125:1243-54

Showing the most recent 10 out of 35 publications